Zymeworks

Historical price data

Zymeworks is a clinical-stage biotech company with a mission to turn scientific innovation into meaningful impact for patients with difficult-to-treat diseases. The company has achieved a significant milestone with the first approval of its partnered asset, zanidatamab (Ziihera®), and is advancing a diverse internal pipeline of next-generation ADCs and multispecific antibodies. Its strategy is built on a dual approach: generating future royalty and milestone cash flows from a portfolio of partnered assets while reinvesting in high-value internal R&D to fuel long-term growth and shareholder returns.

A suite of nine proprietary, interoperable protein engineering platforms enabling the design of multifunctional biotherapeutics, including the Azymetric™ platform for bispecifics and the ZymeLink™ platform for antibody-drug conjugates.

Faces intense competition in ADC space from large pharma and biotech peers, and in multispecifics from platform leaders. Differentiation hinges on demonstrating superior therapeutic indices with its ZymeLink™ payloads and the developability of its Azymetric™ constructs.